CULVER CITY, Calif. & MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation (Altor), a leading developer of novel cytokine-based immunotherapeutics for cancer and infectious diseases and ...
* Development agreement to advance innovative natural killer cell combination immunotherapies for the treatment of cancer * Altor and Co will exclusively collaborate on development of therapeutic ...
July 19 (Reuters) - Altor Bioscience Corp Files To Say It Raised $20 Mln In Equity Financing * Altor Bioscience Corp files to say it raised $20 mln in equity financing - SEC filing ...
Company has already coverted these TCRs to reagents using its STAR technology. Altor BioScience licensed T-cell receptors (TCRs) specific for cells infected by HIV and HCV from Massachusetts General ...
Altor Bioscience Corp., a Miramar, Fla.-based drug company focused on cancer, autoimmune diseases and viral infections, is raising $15 million in Series C funding, according to VentureWire. The ...
SHANGHAI – Beike Biotechnology Co. Ltd., a pioneer in China's stem cell industry, has entered a partnership with Altor Bioscience Corp. in a two-part licensing and equity deal. On the front end, Altor ...
Oct 4 (Reuters) - NantKwest Inc: * Financial terms of this co-development are not disclosed * Development agreement to advance innovative natural killer cell combination immunotherapies for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback